Navigation Links
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Date:1/18/2008

upper respiratory infection (17 percent vs. 13 percent), injection site pain (12 percent vs. 12 percent), headache (12 percent vs. 8 percent), rash (12 percent vs. 6 percent) and sinusitis (11 percent vs. 9 percent). Discontinuations due to adverse events were 7 percent for HUMIRA and 4 percent for placebo. As with any treatment program, the benefits and risks of HUMIRA should be carefully considered before initiating therapy.

In HUMIRA clinical trials for ankylosing spondylitis, psoriatic arthritis, Crohn's disease and plaque psoriasis, the safety profile for adult patients treated with HUMIRA was similar to the safety profile seen in adult patients with rheumatoid arthritis. In placebo-controlled clinical trials in plaque psoriasis, the incidence of arthralgia was 3 percent in HUMIRA-treated patients versus 1 percent in controls.

About HUMIRA

In addition to its approval for chronic plaque psoriasis, HUMIRA is approved by the FDA for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of joint structural damage, and improving physical function in adult patients with moderately to severely active RA. HUMIRA is indicated for reducing the signs and symptoms of active arthritis, inhibiting the progression of structural damage and improving physical function in patients with psoriatic arthritis. HUMIRA resembles antibodies normally found in the body. It works by blocking tumor necrosis factor alpha (TNF-alpha), an inflammatory protein that, when produced in excess, plays a key role in the inflammatory responses of some autoimmune diseases.

To date, HUMIRA has been approved in 72 countries and more than 250,000 people worldwide are currently being treated with HUMIRA. Clinical trials are currently under way evaluating the potential of HUMIRA in other immune-mediated diseases.

In May 2007, Abbott announced it had also submitted an FDA regulatory application for HUMIRA to treat juvenile rheumatoid ar
'/>"/>

SOURCE Abbott
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
3. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
4. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
5. GlaxoSmithKline Receives New HHS Order for H5N1 Bulk Antigen. First North American Clinical Trials with GSKs Candidate Pre-pandemic Flu Vaccine to Start.
6. CryoCor Receives FDA Approval for Right Atrial Flutter
7. Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
8. Dimericine(R) Receives FDA Fast Track Designation for Treatment Of Photosensitivity in XP Patients
9. Poniard Pharmaceuticals Receives FDA Fast Track Designation for Picoplatin for Treatment of Small Cell Lung Cancer
10. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
11. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... NUEVA YORK , 22 de mayo ... (NASDAQ: DPRX ), una compañía farmacéutica ... y comercialización de Locilex® (pexiganan cream 0.8%), ... hoy una presentación de póster destacando el ... fase 3 de la Compañía que evalúan ...
(Date:5/22/2015)... May 22, 2015  BioLife Solutions, Inc. (NASDAQ: BLFS ... grade hypothermic storage and cryopreservation freeze ... and tissues ("BioLife" or the "Company"), announced that the Company ... The Company is scheduled to present at ... 2015 at the Grand Hyatt Hotel in New ...
(Date:5/22/2015)... The leading companies in the cardiac ... rhythm management device market dominate their competition, according ... Jude Medical, Boston Scientific and Asahi Kasei (with ... The healthcare market research publisher,s report, Cardiac ... a base year, providing forecasts for each year ...
Breaking Medicine Technology:Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 2Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 3Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 4Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 5Dipexium anuncia presentación en el séptimo Simposio Internacional sobre el Pie Diabético 6BioLife Solutions To Present At The 2015 Marcum MicroCap Conference In New York City 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4
(Date:5/23/2015)... On Saturday, May 23, 2015, over 100 volunteers ... Florida City exactly five years to the day after the ... A large fire tore through the Branches United Methodist Church ... the middle of the night as neighbors, staff and Branches' ... even though it is suspected that the fire began accidentally. ...
(Date:5/23/2015)... With the implementation of the Affordable ... increasingly difficult to provide their employees with a viable ... insurance for employees stand to face strict penalties. Never ... part of a business’s success or failure. In an ... USA Doctors has created a varying level of less ...
(Date:5/23/2015)... May 23, 2015 Manufacturers are now required ... Factor (HSPF) of 8.2. Experts in the field agree that ... consumers. , The HSPF score is what miles per gallon ... efficient the unit. Although the minimum HSPF score has been ... with an HSPF score north of 12. Indeed, the regulation ...
(Date:5/23/2015)... Add High-Quality prismatic refractions into footage using ProFlare ... simple as dragging and dropping footage into the FCPX timeline ... , Including over 80 stunning flares, ProFlare 5K Prism ... the ultimate bundle for adding prismatic refractions to any video. ... movie files designed for Final Cut Pro X, but are ...
(Date:5/22/2015)... OR (PRWEB) May 22, 2015 Pioneer ... remains at the forefront of designing with reclaimed wood, ... Design in Los Angeles, California. Their newest offerings, Vat ... bring much-anticipated surface and color to America's largest design ... our exhibit at each show, anxious to see and ...
Breaking Medicine News(10 mins):Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 2Health News:Online USA Doctors Now Offers Cost-Saving Alternative Healthcare for Businesses 3Health News:Parker & Sons Welcomes the Department of Energy’s Water Heater Regulation 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 2Health News:Pioneer Millworks to Reveal New Design Trends with Reclaimed Wood at Dwell on Design in LA 3
... of Body By Milk MVP, DANBURY, N.C., Oct. ... nature to the superstar athletes at North Stokes High ... that the,Tigers Varsity football team has earned the title ... was nominated to be part of the,first-ever nationwide Refuel ...
... Isolagen(TM), Inc. (Amex:,ILE) announced today that all injections ... investigating Isolagen Therapy(TM) for the treatment,of moderate to ... all,of the study participants have completed the final ... in the first quarter of,2009., "The second ...
... TrekDesk is a workstation that fits over an existing treadmill and allows ... , ... Phoenix, AZ (Vocus) October 21, 2008 -- Wouldn,t it be wonderful ... improve their health, ward off disease, shed excess weight and make them ...
... Improves Patient Recruitment Process, SAN FRANCISCO, ... of software solutions to optimize clinical trial ... availability of StudyOptimizer,4.0, the latest version of ... patient recruitment process in clinical trials, the ...
... parents with ... disabilities, ... Disabilities and their Families has been established in,Berkeley, California under the ... The Center will oversee several,national research studies concerning parents with disabilities ...
... Remains for Agents that are Effective in,Treating Triple-Negative ... Resources, WALTHAM, Mass., Oct. 21 Decision ... firms for pharmaceutical and,healthcare issues, finds that significant ... over 20 percent of total,sales in the breast ...
Cached Medicine News:Health News:North Carolina School Wins National got milk?(R) Refuel Your School Contest 2Health News:North Carolina School Wins National got milk?(R) Refuel Your School Contest 3Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 2Health News:Isolagen Inc. Completes Injections of Isolagen Therapy(TM) in Phase II/III Acne Scar Study 3Health News:Help Employees Boost Memory, Lose Weight, Get Healthier & Increase Productivity 2Health News:DecisionView Unveils the Next Generation of Clinical Trial Software: StudyOptimizer 4.0 2Health News:DecisionView Unveils the Next Generation of Clinical Trial Software: StudyOptimizer 4.0 3Health News:New National Center for Parents with Disabilities and their Families 2Health News:New National Center for Parents with Disabilities and their Families 3Health News:Genentech/Roche/Chugai's Avastin Will Garner More Than 20 Percent of the Total Breast Cancer Drug Market in 2017 2
Smooth, round edges allow for safe manipulation within the eye. 1.1mm wide gradually tapers to .50 mm wide. 45, 1.1mm wide, gradually tapers to .50mm wide....
Designed to lift corneal cap/flap during corneal lamellar surgery...
Pre-expanded for convenience; no need to pre-soak and fan. Lint-free PVAmaterial...
Angled 45, 9mm from end, Longer design from bend to tip allows for easier placement of viscoelastic to all meridians, Dome shape, extra smooth tip...
Medicine Products: